Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health ...

This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind’s global intellectual property portfolio, which now includes 31 granted patents across 18 ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol ...

(RTTNews) - Clearmind Medicine Inc. (CMND), a clinical-stage biotech company focused on psychedelic-derived therapeutics, announced on Thursday that it has been granted a patent for its MEAI-based ...

Biotech company Clearmind Medicine (CMND) has received the approval of the Institutional Review Board for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder.

Clearmind Medicine Inc. has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development of a proprietary alcohol substitute based on MEAI technology, utilizing Dr ...

Clearmind Medicine (CMND) announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent ...

Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery ...

Clearmind Medicine Inc. Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech ...